Pharmacodynamic and pharmacokinetic effects of TPA023, a GABAA α2,3 subtype-selective agonist, compared to lorazepam and placebo in healthy volunteers

Journal of Psychopharmacology

Volumn 21, Issue 4, 2007, Pages 374-383

  De Haas, S L ^a   De Visser, S J ^a   Van Der Post, J P ^a   De Smet, M ^b   Schoemaker, R C ^a   Rijnbeek, B ^a   Cohen, A F ^a   Vega, J M ^c   Agrawal, N G B ^c   Goel, T V ^c   Simpson, R C ^c   Pearson, L K ^c   Li, S ^c   Hesney, M ^c   Murphy, M G ^c   Van Gerven, J M A ^a  

^a CENTRE FOR HUMAN DRUG RESEARCH   (Netherlands)

^b MSD Europe Inc   (Belgium)

^c MRL   (United States)

Author keywords

Benzodiazepines; Body sway; Memory; Saccadic eye movements; Sedation; Selective partial GABA agonist; TPA023

Indexed keywords

4 AMINOBUTYRIC ACID A RECEPTOR STIMULATING AGENT; LORAZEPAM; PLACEBO; TPA 023; UNCLASSIFIED DRUG;

ADULT; ARTICLE; BODY EQUILIBRIUM; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DIZZINESS; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DROWSINESS; DRUG BLOOD LEVEL; DRUG EFFECT; DRUG INDUCED HEADACHE; DRUG RECEPTOR BINDING; DRUG SELECTIVITY; FATIGUE; HEADACHE; HUMAN; MALE; NEUROPSYCHOLOGICAL TEST; NORMAL HUMAN; PRIORITY JOURNAL; PSYCHOPHARMACOLOGY; RANDOMIZED CONTROLLED TRIAL; RECEPTOR AFFINITY; RECEPTOR SENSITIVITY; SACCADIC EYE MOVEMENT; SEDATION; SINGLE DRUG DOSE; SOMNOLENCE; VISUAL ANALOG SCALE;

ADULT; ANTI-ANXIETY AGENTS; AREA UNDER CURVE; BLOOD PRESSURE; COGNITION; CROSS-OVER STUDIES; DOUBLE-BLIND METHOD; ELECTROCARDIOGRAPHY; HEART RATE; HUMANS; LORAZEPAM; MALE; POSTURE; PYRIDAZINES; RECEPTORS, GABA-A; SACCADES; TRIAZOLES;

EID: 34447573765     PISSN: 02698811     EISSN: 14617285     Source Type: Journal    
DOI: 10.1177/0269881106072343     Document Type: Article

References (56)

1. Aldenkamp A.P., Vermeulen J., Alpherts W C J., Overweg J., van Parijs Jap, Verhoeff N P L G. (1992) Validity of computerized testing: patient dysfunction and complaints versus measured changes. In Dodson W E, Kinsbourne M (eds). Assessment of Cognitive Function. Demos, New York, pp. 51 - 68
2. Alpherts W C J (1987) Computers as a technique for neurophysiological assessment in epilepsy. In Aldenkamp A P, Alpherts W C J, Meinardi H, Stores G (eds). Education and Epilepsy, Swets & Zeitlinger, Lisse / Berwyn, pp. 101 - 109
3. Atack J.R. (2003) Anxioselective compounds acting at the GABA(A) receptor benzodiazepine binding site. Curr Drug Targets CNS Neurol Disord 2: 213 - 232
4. Atack J.R. (2005) The benzodiazepine binding site of GABA(A) receptors as a target for the development of novel anxiolytics. Expert Opin Investig Drugs 14: 601 - 618
5. Atack J.R., Hutson P.H., Collinson N., Marshall G., Bentley G., Moyes C., Cook S.M., Collins I., Wafford K., McKernan R.M., Dawson G.R. (2005) Anxiogenic properties of an inverse agonist selective for alpha3 subunit-containing GABA A receptors. Br J Pharmacol 144: 357 - 366
6. Atack J.R., Wafford K.A., Tye S.J., Cook S.M., Sohal B., Pike A., Sur C., Melillo D., Bristow L., Bromidge F., Ragan I., Kerby J., Street L., Carling R., Castro J.L., Whiting P., Dawson G.R., McKernan R.M. (2006) TPA023 [7-(1,1-Dimethylethyl)-6-(2-ethyl-2H-1,2,4-triazol-3-ylmethoxy)-3-(2-fluor ophenyl)-1,2,4-triazolo[4,3-b]pyridazine], an agonist selective for {alpha}2- and {alpha}3-containing GABAA receptors, is a nonsedating anxiolytic in rodents and primates. J Pharmacol Exp Ther 316: 410 - 422
7. Aufdembrinke B. (1998) Abecarnil, a new beta-carboline, in the treatment of anxiety disorders. Br J Psychiatry (suppl.). 55 - 63
8. Basile A.S., Lippa A.S., Skolnick P. (2004) Anxioselective anxiolytics: can less be more? Eur J Pharmacol 500: 441 - 451
9. Bond A., Lader M. (1974) The use of analogue scales in rating subjective feelings. Br J Med Psychol 47: 211 - 218
10. Brunette M.F., Noordsy D.L., Xie H., Drake R.E. (2003) Benzodiazepine use and abuse among patients with severe mental illness and co-occurring substance use disorders. Psychiatr Serv 54: 1395 - 1401
11. Carling R.W., Moore K.W., Street L.J., Wild D., Isted C., Leeson P.D., Thomas S., O'Connor D., McKernan R.M., Quirk K., Cook S.M., Atack J.R., Wafford K.A., Thompson S.A., Dawson G.R., Ferris P., Castro J.L. (2004) 3-phenyl-6-(2-pyridyl)methyloxy-1,2,4-triazolo[3,4-a]phthalazines and analogues: high-affinity gamma-aminobutyric acid-A benzodiazepine receptor ligands with alpha 2, alpha 3, and alpha 5-subtype binding selectivity over alpha 1. J Med Chem 47: 1807 - 1822
12. Carling R.W., Madin A., Guiblin A., Russell M.G., Moore K.W., Mitchinson A., Sohal B., Pike A., Cook S.M., Ragan I.C., McKernan R.M., Quirk K., Ferris P., Marshall G., Thompson S.A., Wafford K.A., Dawson G.R., Atack J.R., Harrison T., Castro J.L., Street L J. (2005) 7-(1,1-Dimethylethyl)-6-(2-ethyl-2H-1,2,4- triazol-3-ylmethoxy)-3-(2-fluoro phenyl)-1,2,4-triazolo[4,3-b]pyridazine: a functionally selective gamma-aminobutyric acid(A) (GABA(A). alpha2/alpha3- subtype selective agonist that exhibits potent anxiolytic activity but is not sedating in animal models. J Med Chem 48: 7089 - 7092
13. Clark R.E., Xie H., Brunette M.F. (2004) Benzodiazepine prescription practices and substance abuse in persons with severe mental illness. J Clin Psychiatry 65: 151 - 155
14. Cohen A.F., Hamilton M.J., Peck A.W. (1987) The effects of acrivastine (BW825C). diphenhydramine and terfenadine in combination with alcohol on human CNS performance. Eur J Clin Pharmacol 32: 279 - 288
15. Collinson N., Kuenzi F.M., Jarolimek W., Maubach K.A., Cothliff R., Sur C., Smith A., Otu F.M., Howell O., Atack J.R., McKernan R.M., Seabrook G.R., Dawson G.R., Whiting P.J., Rosahl T.W. (2002) Enhanced learning and memory and altered GABAergic synaptic transmission in mice lacking the alpha 5 subunit of the GABAA receptor. J Neurosci 22: 5572 - 5580
16. Dawson G.R., Maubach K.A., Collinson N., Cobain M., Everitt B.J., MacLeod A.M., Choudhury H.I., McDonald L.M., Pillai G., Rycroft W., Smith A.J., Sternfeld F., Tattersall F.D., Wafford K.A., Reynolds D.S., Seabrook G.R., Atack J.R. (2006) An inverse agonist selective for alpha5 subunit-containing GABAA receptors enhances cognition. J Pharmacol Exp Ther 316: 1335 - 1345
17. de Visser S.J., van Gerven J.M., Schoemaker R.C., Cohen A.F. (2001) Concentration-effect relationships of two infusion rates of the imidazoline antihypertensive agent rilmenidine for blood pressure and development of side-effects in healthy subjects. Br J Clin Pharmacol 51: 423 - 428
18. de Visser S.J., van der Post J.P., de Waal P.P., Cornet F., Cohen A.F., van Gerven J.M. (2003) Biomarkers for the effects of benzodiazepines in healthy volunteers. Br J Clin Pharmacol 55: 39 - 50
19. Dias R., Sheppard W.F., Fradley R.L., Garrett E.M., Stanley J.L., Tye S.J., Goodacre S., Lincoln R.J., Cook S.M., Conley R., Hallett D., Humphries A.C., Thompson S.A., Wafford K.A., Street L.J., Castro J.L., Whiting P.J., Rosahl T.W., Atack J.R., McKernan R.M., Dawson G.R., Reynolds D.S. (2005) Evidence for a significant role of alpha3-containing GABAA receptors in mediating the anxiolytic effects of benzodiazepines. J Neurosci 25: 10682 - 10688
20. Dingemanse J., Bury M., Bock J., Joubert P. (1995) Comparative pharmacodynamics of Ro 41-3696, a new hypnotic, and zolpidem after nighttime administration to healthy subjects. Psychopharmacology (Berl) 122: 169 - 174
21. Gliatto M.F. (2000) Generalized anxiety disorder. Am Fam Physician 62: 1591 - 600, 1602
22. Glue P., White E., Wilson S., Ball D.M., Nutt D.J. (1991) Pharmacology of saccadic eye movements in man. 2. Effects of the alpha 2-adrenoceptor ligands idazoxan and clonidine. Psychopharmacology (Berl) 105: 368 - 373
23. Green J.F., King D.J., Trimble K.M. (2000) Antisaccade and smooth pursuit eye movements in healthy subjects receiving sertraline and lorazepam. J Psychopharmacol 14: 30 - 36
24. Green J.F., McElholm A., King D.J. (1996) A comparison of the sedative and amnestic effects of chlorpromazine and lorazepam. Psychopharmacology (Berl) 128: 67 - 73
25. Griebel G., Perrault G., Simiand J., Cohen C., Granger P., Depoortere H., Francon D., Avenet P., Schoemaker H., Evanno Y., Sevrin M., George P., Scatton B. (2003) SL651498, a GABAA receptor agonist with subtypeselective efficacy, as a potential treatment for generalized anxiety disorder and muscle spasms. CNS Drug Rev 9: 3 - 20
26. Griebel G., Perrault G., Simiand J., Cohen C., Granger P., Decobert M., Francon D., Avenet P., Depoortere H., Tan S., Oblin A., Schoemaker H., Evanno Y., Sevrin M., George P., Scatton B. (2001) SL651498: an anxioselective compound with functional selectivity for alpha2- and alpha3-containing gamma-aminobutyric acid(A) (GABA(A). receptors. J Pharmacol Exp Ther 298: 753 - 768
27. Griffiths A.N., Jones D.M., Richens A. (1986) Zopiclone produces effects on human performance similar to flurazepam, lormetazepam and triazolam. Br J Clin Pharmacol 21: 647 - 653
28. Ihmsen H., Albrecht S., Hering W., Schuttler J., Schwilden H. (2004) Modelling acute tolerance to the EEG effect of two benzodiazepines. Br J Clin Pharmacol 57: 153 - 161
29. Johnstone T.B., Hogenkamp D.J., Coyne L., Su J., Halliwell R.F., Tran M.B., Yoshimura R.F., Li W.Y., Wang J., Gee K.W. (2004) Modifying quinolone antibiotics yields new anxiolytics. Nat Med 10: 31 - 32
30. Low K., Crestani F., Keist R., Benke D., Brunig I., Benson J.A., Fritschy J.M., Rulicke T., Bluethmann H., Mohler H., Rudolph U. (2000) Molecular and neuronal substrate for the selective attenuation of anxiety. Science 290: 131 - 134
31. McKernan R.M., Rosahl T.W., Reynolds D.S., Sur C., Wafford K.A., Atack J.R., Farrar S., Myers J., Cook G., Ferris P., Garrett L., Bristow L., Marshall G., Macaulay A., Brown N., Howell O., Moore K.W., Carling R.W., Street L.J., Castro J.L., Ragan C.I., Dawson G.R., Whiting PJ (2000) Sedative but not anxiolytic properties of benzodiazepines are mediated by the GABA(A) receptor alpha1 subtype. Nat Neurosci 3: 587 - 592
32. Madhusoodanan S., Bogunovic O.J. (2004) Safety of benzodiazepines in the geriatric population. Expert Opin Drug Saf 3: 485 - 493
33. Micallef J., Soubrouillard C., Guet F., Le Guern M.E., Alquier C., Bruguerolle B., Blin O. (2001) A double blind parallel group placebo controlled comparison of sedative and amnesic effects of etifoxine and lorazepam in healthy subjects. Fundam Clin Pharmacol 15: 209 - 216
34. Mohler H., Crestani F., Rudolph U. (2001) GABA(A)-receptor subtypes: a new pharmacology. Curr Opin Pharmacol 1: 22 - 25
35. Nelson R.E., Dickson A.L., Banos J.H. (2000) An automated administration of Corsi's block-tapping test. Percept Mot Skills 91: 578 - 580
36. Norris H. (1971) The action of sedatives on brain stem oculomotor systems in man. Neuropharmacology 10: 181 - 191
37. Oliva G.A., Bucci M.P., Fioravanti R. (1993) Impairment of saccadic eye movements by scopolamine treatment. Percept Mot Skills 76: 159 - 167
38. Paterniti S., Dufouil C., Alperovitch A. (2002) Long-term benzodiazepine use and cognitive decline in the elderly: the Epidemiology of Vascular Aging Study. J Clin Psychopharmacol 22: 285 - 293
39. Pollack M.H., Worthington J.J., Manfro G.G., Otto M.W., Zucker B.G. (1997) Abecarnil for the treatment of generalized anxiety disorder: a placebo-controlled comparison of two dosage ranges of abecarnil and buspirone. J Clin Psychiatry 58 (suppl. 11). 19 - 23
40. Puia G., Ducic I., Vicini S., Costa E. (1992) Molecular mechanisms of the partial allosteric modulatory effects of bretazenil at gamma-aminobutyric acid type A receptor. Proc Natl Acad Sci USA 89: 3620 - 3624
41. Ray W.A., Thapa P.B., Gideon P. (2000) Benzodiazepines and the risk of falls in nursing home residents. J Am Geriatr Soc 48: 682 - 685
42. Rudolph U., Crestani F., Mohler H. (2001) GABA(A) receptor subtypes: dissecting their pharmacological functions. Trends Pharmacol Sci 22: 188 - 194
43. Rudolph U., Crestani F., Benke D., Brunig I., Benson J.A., Fritschy J.M., Martin J.R., Bluethmann H., Mohler H. (1999) Benzodiazepine actions mediated by specific gamma-aminobutyric acid(A) receptor subtypes. Nature 401: 796 - 800
44. Schoemaker R.C., Cohen A.F. (1996) Estimating impossible curves using NONMEM. Br J Clin Pharmacol 42: 283 - 290
45. Sigel E., Buhr A. (1997) The benzodiazepine binding site of GABAA receptors. Trends Pharmacol Sci 18: 425 - 429
46. Smith G.B., Olsen R.W. (1995) Functional domains of GABAA receptors. Trends Pharmacol Sci 16: 162 - 168
47. Soo-Ampon S., Wongwitdecha N., Plasen S., Hindmarch I., Boyle J. (2004) Effects of word frequency on recall memory following lorazepam, alcohol, and lorazepam alcohol interaction in healthy volunteers. Psychopharmacology (Berl) 176: 420 - 425
48. Tobler I., Kopp C., Deboer T., Rudolph U. (2001) Diazepam-induced changes in sleep: role of the alpha 1 GABA(A) receptor subtype. Proc Natl Acad Sci USA 98: 6464 - 6469
49. van Steveninck A.L., Cohen A.F., Ward T. (1989) A microcomputer based system for recording and analysis of smooth pursuit and saccadic eye movements. Br J Clin Pharmacol 27: 712P - 713P
50. van Steveninck A.L., Schoemaker H.C., Pieters M.S., Kroon R., Breimer D.D., Cohen A.F. (1991) A comparison of the sensitivities of adaptive tracking, eye movement analysis and visual analog lines to the effects of incremental doses of temazepam in healthy volunteers. Clin Pharmacol Ther 50: 172 - 180
51. van Steveninck A.L., van Berckel B.N., Schoemaker R.C., Breimer D.D., van Gerven J.M., Cohen A.F. (1999) The sensitivity of pharmacodynamic tests for the central nervous system effects of drugs on the effects of sleep deprivation. J Psychopharmacol 13: 10 - 17
52. van Steveninck A.L., Gieschke R., Schoemaker H.C., Pieters M.S., Kroon J.M., Breimer D.D., Cohen A.F. (1993) Pharmacodynamic interactions of diazepam and intravenous alcohol at pseudo steady state. Psychopharmacology (Berl) 110: 471 - 478
53. van Steveninck A.L., Verver S., Schoemaker H.C., Pieters M.S., Kroon R., Breimer D.D., Cohen A.F. (1992) Effects of temazepam on saccadic eye movements: concentration-effect relationships in individual volunteers. Clin Pharmacol Ther 52: 402 - 408
54. van Steveninck A.L., Wallnofer A.E., Schoemaker R.C., Pieters M.S., Danhof M., van Gerven J.M., Cohen A.F. (1997) A study of the effects of long-term use on individual sensitivity to temazepam and lorazepam in a clinical population. Br J Clin Pharmacol 44: 267 - 275
55. van Steveninck A.L., Gieschke R., Schoemaker R.C., Roncari G., Tuk B., Pieters M.S., Breimer D.D., Cohen A.F. (1996) Pharmacokinetic and pharmacodynamic interactions of bretazenil and diazepam with alcohol. Br J Clin Pharmacol 41: 565 - 573
56. Wright B.M. (1971) A simple mechanical ataxia-meter. J Physiol 218: 27P - 28P